A. Little

发表

Mechanisms of acquired resistance to ERK1/2 pathway inhibitors

S J Cook, S. Cook, A. Little, 2013, Oncogene.

Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance

S. Lawo, C. le Sage, N. McCarthy, 2017, Scientific Reports.

Increasing the performance of pooled CRISPR–Cas9 drop-out screening

Jonathan D. Moore, Benedict C. S. Cross, Steffen Lawo, 2016, Scientific Reports.

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

P. Edwards, S. Cook, J. Dry, 2011, Science Signaling.

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.

S. Cook, Paul D. Smith, K. Balmanno, 2012, Biochemical Society transactions.

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

S. Cook, K. Balmanno, K. Balmanno, 2013, Oncogene.

Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance

Syed Asad Rahman, Annette S. Little, S. Lawo, 2017, Scientific Reports.

Identification of approved and investigational drugs that inhibit hypoxia-inducible factor-1 signaling

Ruili Huang, M. Xia, Chia-Wen Hsu, 2016, Oncotarget.

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

P. Edwards, S. Cook, J. Dry, 2011, Science Signaling.